Orasis Pharmaceuticals
Orasis Pharmaceuticals is an ophthalmic pharmaceutical company dedicated to advancing vision care through innovative solutions. The company is focused on the development and commercialization of Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4%, a novel eye drop designed to treat presbyopia in adults.
Leadership & Board
- Current Number of Employees
- 66
- Current LinkedIn Followers
- 8,258
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $78M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $78M
- Latest Funding Round
- Series D
- Post-Money Valuation
- ―
Employee Trend
Orasis Pharmaceuticals had 66 employees as of October 12, 2026. The number of employees decreased by 2 (2.94%) week-over-week.
66Latest Employee Count
2(-2.94%)Week-Over-Week Change
Social Trend
Orasis Pharmaceuticals had 8,258 followers as of October 12, 2026. The number of followers increased by 3 (0.04%) week-over-week.
8,258Latest Followers Count
3(0.04%)Week-Over-Week Change
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Aug 14, 2025 | Series D | $78.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Sequoia Capital | Series D |
| Arboretum Ventures | Series D |
| Johnson & Johnson Innovation – JJDC Inc. | Series D |
| Catalio Capital Management | Series D |
| Freepoint Capital Group | Series D |
| Visionary Ventures | Series D |
| Bluestem Capital | Series D |
| SBI | Series D |
Similar Companies
A snapshot of private companies similar to Orasis Pharmaceuticals, helping you discover and navigate related company profiles.
